)
Edge26 Jun 2026
The Universal Language: Inventing the Barcode
How lines in the sand on a Miami beach became the most scanned symbol in human history, and why it took decades for anyone to care.
Clearmind Medicine
Clearmind Medicine (CMND) investor relations material
Clearmind Medicine Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary15 Jun, 2026
Executive summary
Engaged in phase I/IIa clinical trials for novel psychedelic medicines, with R&D primarily in Israel.
No revenue generated for the six months ended April 30, 2026; operations funded by equity and convertible loans.
Significant share structure changes due to two reverse splits during the period.
Financial highlights
Net loss for six months ended April 30, 2026 was $5,902,236, compared to $1,855,549 for the same period in 2025.
Operating expenses rose to $5,231,124 from $2,803,155 year-over-year, driven by higher G&A and R&D costs.
Cash and cash equivalents increased to $11,415,719 as of April 30, 2026, up from $3,923,058 at October 31, 2025.
Financing activities provided $11,995,163 in cash, mainly from share issuances and convertible loans.
Outlook and guidance
Management believes sufficient working capital will be obtained from external financing, but substantial doubt remains about the ability to continue as a going concern.
Ongoing regional conflicts in Israel present operational uncertainties for clinical trials and business continuity.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Clearmind Medicine
- Psychedelic drug developer seeks $10M convertible note to fund trials, enabling resale of up to 22.6M shares.CMND
Registration filing30 Apr 2026 - Net loss increased to $3.85M as R&D and admin costs rose, with cash boosted to $9.26M.CMNDQ1 202615 Apr 2026
- Novel psychedelic AUD therapy in clinical trials, funded by convertible notes, faces dilution and geopolitical risks.CMNDRegistration Filing17 Feb 2026
- Net loss narrowed, but ongoing losses, no revenue, and funding needs raise going concern risk.CMNDQ4 202520 Jan 2026
- Developing psychedelic therapies for AUD and obesity, but faces ongoing losses and high risk.CMNDRegistration Filing5 Dec 2025
- Registering up to 17M shares for resale, funding R&D of non-hallucinogenic psychedelic therapies.CMNDRegistration Filing29 Nov 2025
- Psychedelic drug developer registers resale of 5.78M shares amid clinical trials and compliance risks.CMNDRegistration Filing26 Nov 2025
- Clinical trials advanced, net loss narrowed, but future financing remains critical.CMNDQ3 202522 Sep 2025
- Net loss of $1.86M, no revenue, and continued reliance on external financing amid ongoing risks.CMNDQ2 202530 Jun 2025
Next Clearmind Medicine earnings date
Q3 202610 Sep, 2026
Clearmind Medicine
Next Clearmind Medicine earnings date
Q3 202610 Sep, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage